IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors
MWN-AI** Summary
IDEAYA Biosciences, a precision medicine oncology company, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE892, a promising MTA-cooperative PRMT5 inhibitor aimed at treating solid tumors with MTAP deletions, particularly lung cancer. The company anticipates commencing a Phase 1 dose escalation trial by the fourth quarter of 2025, with a focus on utilizing IDE892 as a monotherapy and in combination with IDE397, its proprietary MAT2A inhibitor, in subsequent studies planned for early 2026.
MTAP deletions occur in approximately 15-20% of non-small cell lung cancer (NSCLC) cases, creating a unique vulnerability in these tumors where elevated MTA/SAM ratios can be therapeutically targeted through PRMT5 inhibition. IDEAYA believes that combining IDE892 with MAT2A inhibitors could significantly enhance anti-tumor activity, thus presenting a critical opportunity in an area known for its substantial unmet medical needs.
Michael White, IDEAYA's Chief Scientific Officer, highlighted the project as the result of extensive optimization in biophysical and pharmacokinetic properties, ultimately aiming to position IDE892 as a "best-in-class" option for treating MTAP-deleted cancers. The upcoming 10-Year Anniversary R&D Day on September 8 will further showcase the preclinical findings of IDE892 and its strategic combination with IDE397.
IDEAYA's overarching goal is to advance innovative therapies that offer more targeted, effective, and personalized treatments for cancer, significantly improving patient outcomes. The announcement of IDE892's IND submission underscores IDEAYA's commitment to leveraging genetic insights to develop revolutionary oncology therapies.
MWN-AI** Analysis
IDEAYA Biosciences (Nasdaq: IDYA) has made significant strides with its recent IND submission for IDE892, a novel PRMT5 inhibitor aimed at treating MTAP-deleted solid tumors, particularly in non-small cell lung cancer (NSCLC). As the company prepares for its Phase 1 dose escalation trial targeting MTAP-deleted lung cancer by Q4 2025, investors should keenly observe several key factors that might influence IDEAYA's market performance.
Firstly, the promising preclinical profile of IDE892 augments its potential as a best-in-class therapeutic agent. Given that 15-20% of NSCLC cases are characterized by MTAP deletions, IDEAYA is strategically positioning itself within a significant market segment with substantial unmet medical needs. The company's targeted focus on combination therapies, particularly its synergy with IDE397, heralds a compelling opportunity for enhancing the efficacy of treatments currently available for these patients.
However, challenges remain inherent within the biopharmaceutical sphere, including the necessity for rigorous clinical trial processes and the unpredictable nature of regulatory approvals. Investors should be aware that while the therapeutic potential of IDE892 is notable, its transition from preclinical to clinical phases carries inherent risks.
The upcoming R&D Day on September 8th presents a valuable opportunity for the company to provide further insights regarding IDE892's profile and its strategic roadmap. This event may serve as a catalyst for stock price movement, especially if new data substantiates the efficacy and safety of IDE892.
In summary, IDEAYA Biosciences presents a compelling investment thesis given its innovative treatment approach for MTAP-deleted tumors. Potential investors should monitor developments closely while weighing the inherent risks of clinical drug development. A prudent approach would be to stay informed about trial outcomes and industry trends that may impact IDEAYA's trajectory in the oncology market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- Dosing of first patient in Phase 1 dose escalation trial of IDE892 targeted in 4Q 2025
- Preclinical profile of IDE892 and mechanistic combination rationale with IDE397, IDEAYA's proprietary MAT2A inhibitor, will be presented at the 10-Year Anniversary R&D Day on September 8 th
SOUTH SAN FRANCISCO, Calif. , Sept. 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE892, a potential best-in-class MTA-cooperative inhibitor of PRMT5. The company is targeting to begin a Phase 1 dose escalation trial of IDE892 in MTAP-deleted lung cancer in the fourth quarter of 2025, with the goal of advancing into combination trials with IDE397, IDEAYA's proprietary MAT2A inhibitor, in the first half of 2026.
Approximately 15-20% of non-small cell lung cancer (NSCLC) is MTAP-deleted. Extensive studies indicate that elevated MTA/SAM ratios in MTAP-deleted cancers create a tumor-specific vulnerability to MTA-cooperative PRMT5 inhibition. This effect is substantially enhanced in combination with MAT2A inhibition, leading to an important combination therapy opportunity in an area of substantial unmet need. In addition to MTAP-deleted lung cancer, IDEAYA will target to clinically evaluate other high priority MTAP solid tumor indications as both IDE892 monotherapy and in combination with IDE397.
"We are excited to advance IDE892 into clinical studies for patients with MTAP-deleted lung cancer, where we believe the inhibition of PRMT5 in combination with MAT2A could have synergistic anti-tumor activity," said Michael White , Chief Scientific Officer, IDEAYA Biosciences. "IDE892 is the culmination of a comprehensive optimization of the biophysical and pharmacokinetic properties required to maximize therapeutic benefit as a combination partner with IDE397, and to generate a potential best-in-class MTA-cooperative PRMT5 inhibitor profile."
Registration for IDEAYA's 10-Year Anniversary R&D Day can be accessed here or at the investors section of the IDEAYA website at https://ir.ideayabio.com/events .
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the potential therapeutic benefits of IDEAYA therapeutics, including combination therapies; (ii) the timing and content of IDEAYA's 10-Year Anniversary R&D Day; (iii) the timing of dosing of first patient in Phase 1 dose escalation trial for IDE892; (iv) the timing of initiating studies for IDE892/IDE397 combination; and (v) the estimated occurrence of MTAP-deletion in NSCLC. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' in early or late stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski , Ph.D.
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
FAQ**
What specific clinical endpoints does IDEAYA Biosciences Inc. IDYA aim to achieve in the upcoming Phase 1 trial for IDE892 targeting MTAP-deleted solid tumors?
How does IDEAYA Biosciences Inc. IDYA plan to mitigate the risks and uncertainties associated with regulatory approvals for IDE892 and its combination with IDE397?
Given the prevalence of MTAP-deletion in non-small cell lung cancer, what market potential does IDEAYA Biosciences Inc. IDYA anticipate for IDE892 in this specific segment?
What are the key differentiators of IDE892 that IDEAYA Biosciences Inc. IDYA believes establish it as a potential best-in-class MTA-cooperative PRMT5 inhibitor compared to existing therapies?
**MWN-AI FAQ is based on asking OpenAI questions about IDEAYA Biosciences Inc. (NASDAQ: IDYA).
NASDAQ: IDYA
IDYA Trading
5.7% G/L:
$34.33 Last:
45,974 Volume:
$33.43 Open:
